Skip to content

Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry

The Clinical Outcomes After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Colorectal Neoplasms - A Multicenter Registry

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05653960
Enrollment
2500
Registered
2022-12-16
Start date
2024-12-01
Completion date
2033-12-31
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenoma, Colorectal Cancer, Colorectal Neoplasms

Keywords

Endoscopic mucosal resection, Endoscopic submucosal dissection

Brief summary

This study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.

Detailed description

Colorectal cancer (CRC) is one of the most common causes of cancer-related death, however its morbidity and mortality can be reduced by colonoscopy screening and endoscopic removal of adenomas or early cancers.\[1\] Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms. Despite being a safe and convenient procedure, insufficient resection by EMR can result in a high risk of local recurrence, particularly in lesions ≥ 20 mm. Compared with EMR, ESD facilitates a higher rate of en bloc resection and a lower rate of local recurrence. A recent meta-analysis revealed that the local recurrence rate after colorectal ESD was 1% during a 2-year follow-up period. In addition, ESD can facilitate precise pathological diagnosis to assess the risk of lymph node metastasis of early CRC to judge whether salvage surgery is needed. Although the efficacy of colorectal ESD has been demonstrated, its usage is largely limited by its technical difficulty and risk of complications. Both short- and long-term data on clinical outcomes and safety profiles for colorectal EMR and ESD are needed. Therefore, this study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.

Interventions

OTHEREMR or ESD

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years

Inclusion criteria

* Subjects who undergo EMR or ESD for colorectal lesions.

Exclusion criteria

* Not applicable.

Design outcomes

Primary

MeasureTime frameDescription
Curative resection rate of EMR or ESD for colorectal neoplasms10 yearsThe short- and long-term clinical efficacy outcomes of colorectal EMR or ESD
Adverse event rate of EMR or ESD for colorectal neoplasms10 yearsThe short- and long-term clinical safety outcomes of colorectal EMR or ESD

Countries

Hong Kong

Contacts

Primary ContactLouis Lau
louishslau@cuhk.edu.lhk6049 0760

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026